AU2001288373B2 - Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers - Google Patents

Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers Download PDF

Info

Publication number
AU2001288373B2
AU2001288373B2 AU2001288373A AU2001288373A AU2001288373B2 AU 2001288373 B2 AU2001288373 B2 AU 2001288373B2 AU 2001288373 A AU2001288373 A AU 2001288373A AU 2001288373 A AU2001288373 A AU 2001288373A AU 2001288373 B2 AU2001288373 B2 AU 2001288373B2
Authority
AU
Australia
Prior art keywords
bcl
cancer
dose
antisense oligomer
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001288373A
Other languages
English (en)
Other versions
AU2001288373A1 (en
Inventor
Howard Fingert
Robert E. Klem
Raymond P. Warrel Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001288373(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Inc filed Critical Genta Inc
Publication of AU2001288373A1 publication Critical patent/AU2001288373A1/en
Application granted granted Critical
Publication of AU2001288373B2 publication Critical patent/AU2001288373B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001288373A 2000-08-25 2001-08-23 Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers Ceased AU2001288373B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US60/227,970 2000-08-25
US23700900P 2000-09-29 2000-09-29
US60/237,009 2000-09-29
US09/709,170 2000-11-10
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2001/026414 WO2002017852A2 (fr) 2000-08-25 2001-08-23 Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2

Publications (2)

Publication Number Publication Date
AU2001288373A1 AU2001288373A1 (en) 2002-06-06
AU2001288373B2 true AU2001288373B2 (en) 2006-05-11

Family

ID=27397795

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001288373A Ceased AU2001288373B2 (en) 2000-08-25 2001-08-23 Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
AU8837301A Pending AU8837301A (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8837301A Pending AU8837301A (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Country Status (33)

Country Link
US (2) US7795232B1 (fr)
EP (2) EP2135623A1 (fr)
JP (1) JP2004507480A (fr)
KR (1) KR20030034153A (fr)
CN (1) CN1471408A (fr)
AP (1) AP2003002761A0 (fr)
AT (1) ATE432717T1 (fr)
AU (2) AU2001288373B2 (fr)
BG (1) BG107641A (fr)
BR (1) BR0113447A (fr)
CA (1) CA2419480A1 (fr)
CY (1) CY1109340T1 (fr)
CZ (1) CZ301582B6 (fr)
DE (1) DE60138892D1 (fr)
DK (1) DK1313514T3 (fr)
DZ (1) DZ3471A1 (fr)
EA (1) EA005424B1 (fr)
EE (1) EE200300074A (fr)
ES (1) ES2327904T3 (fr)
GE (1) GEP20063934B (fr)
HK (1) HK1056505A1 (fr)
HR (1) HRP20030102A2 (fr)
HU (1) HUP0303125A2 (fr)
IL (1) IL154409A0 (fr)
MX (1) MXPA03001575A (fr)
NO (1) NO20030858L (fr)
OA (1) OA12586A (fr)
PL (1) PL363050A1 (fr)
PT (1) PT1313514E (fr)
SK (1) SK3652003A3 (fr)
UA (1) UA77945C2 (fr)
WO (1) WO2002017852A2 (fr)
YU (1) YU13603A (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
JP2005519624A (ja) 2002-03-13 2005-07-07 ジェノミック ヘルス， インコーポレイテッド 生検腫瘍組織での遺伝子発現プロファイリング
JP2006514546A (ja) * 2002-11-14 2006-05-11 ジェンタ・サルース・リミテッド・ライアビリティ・カンパニー Ｂｃｌ−２を標的とする抑制性オリゴヌクレオチド
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1597391B1 (fr) 2003-02-20 2008-10-29 Genomic Health, Inc. Utilisation d'arn intronique pour mesurer l'expression genique
CA2527109A1 (fr) 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Arn oligobicatenaire inhibant l'expression de bcl-2 et composition medicinale contenant cet arn
PL3470535T3 (pl) 2003-06-24 2020-08-24 Genomic Health, Inc. Prognozowanie prawdopodobieństwa ponownego wystąpienia raka
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DE602004031368D1 (de) 2003-12-23 2011-03-24 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
EP1791959A4 (fr) 2004-08-26 2009-03-18 Enegenic Gene Therapy Pty Ltd Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries
CA2585561C (fr) 2004-11-05 2018-07-17 Genomic Health, Inc. Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement
CA3061785A1 (fr) 2004-11-05 2006-05-18 Genomic Health, Inc. Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique
ES2419106T3 (es) * 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Formulación de liposomas anfóteros
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (fr) * 2007-12-07 2009-06-11 Santaris Pharma A/S Composés d'antagoniste d'arn utiles pour moduler bcl-2
AU2009316773A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
MX2012001244A (es) 2009-07-30 2012-03-26 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta.
CN102822342B (zh) * 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
EP3319995B1 (fr) * 2015-07-07 2019-04-17 H. Hoffnabb-La Roche Ag Polythérapie avec un conjugué médicament-anticorps anti-her2 et un inhibiteur de bcl -2
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
WO2021231486A1 (fr) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Traitement du cancer par l'induction de sénescence suivie d'un sénolytique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
CA2025907A1 (fr) 1989-09-21 1991-03-22 Franklin D. Collins Methode pour le transport de composes a travers la barriere hemato-encephalique
WO1993020200A1 (fr) 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Cellules modifiees et procede de traitement
DE69330137T2 (de) 1992-10-21 2001-11-15 Univ Temple Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Docs cited in WO 02/17852 *

Also Published As

Publication number Publication date
WO2002017852A2 (fr) 2002-03-07
CZ2003848A3 (cs) 2003-11-12
NO20030858D0 (no) 2003-02-24
ATE432717T1 (de) 2009-06-15
DK1313514T3 (da) 2009-10-12
CN1471408A (zh) 2004-01-28
BG107641A (bg) 2004-01-30
PT1313514E (pt) 2009-09-01
EA200300294A1 (ru) 2003-08-28
OA12586A (en) 2006-06-07
ES2327904T3 (es) 2009-11-05
HRP20030102A2 (en) 2005-04-30
JP2004507480A (ja) 2004-03-11
EP1313514A4 (fr) 2005-07-13
HUP0303125A2 (hu) 2003-12-29
DE60138892D1 (de) 2009-07-16
CA2419480A1 (fr) 2002-03-07
EP1313514B1 (fr) 2009-06-03
UA77945C2 (en) 2007-02-15
MXPA03001575A (es) 2004-11-01
NO20030858L (no) 2003-04-24
CY1109340T1 (el) 2014-07-02
DZ3471A1 (fr) 2002-03-07
SK3652003A3 (en) 2003-08-05
CZ301582B6 (cs) 2010-04-21
GEP20063934B (en) 2006-10-10
AP2003002761A0 (en) 2003-06-30
US7795232B1 (en) 2010-09-14
AU8837301A (en) 2002-03-13
PL363050A1 (en) 2004-11-15
KR20030034153A (ko) 2003-05-01
YU13603A (sh) 2006-05-25
WO2002017852A3 (fr) 2003-04-03
EE200300074A (et) 2004-12-15
IL154409A0 (en) 2003-09-17
EA005424B1 (ru) 2005-02-24
US20100216867A1 (en) 2010-08-26
EP1313514A2 (fr) 2003-05-28
BR0113447A (pt) 2003-07-08
EP2135623A1 (fr) 2009-12-23
HK1056505A1 (en) 2004-02-20

Similar Documents

Publication Publication Date Title
AU2001288373B2 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
AU2001288373A1 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
US20040147473A1 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
JP7021076B2 (ja) Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法
US7060690B2 (en) Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
AU2010202302A1 (en) Antisense Oligonucleotides directed to Ribonucleotide reductase R2 and uses thereof in the treatment of cancer
WO2004056971A2 (fr) Methodes de traitement d'un trouble associe au bcl-2 a l'aide d'oligomeres anti-sens bcl-2
US7662792B2 (en) Modulation of Fas and FasL expression
JP6437930B2 (ja) 悪性胸膜中皮腫を治療するためのマイクロｒｎａを基にしたアプローチ
Kausch et al. Antisense oligonucleotide therapy in urology
JP2009540857A (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
US7855183B2 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
ZA200301161B (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers.
CN114196675A (zh) 靶向linc00624的反义寡核苷酸及其在乳腺癌治疗中的应用
EP1313853B1 (fr) Modulation de l'expression de fas et fasl par un oligonucléotide phosphodiester synthétique et un anticorps anti-fas
US20060135450A1 (en) Combinations of antisense oligonucleotides directed against thymidylate synthase mrna and uses thereof
ES2383671T3 (es) Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas
WO2008002470A2 (fr) SÉQUENCES D'ARNsi CONTRE LE BRF1
WO2012018594A2 (fr) Polysaccharides d'origine végétale pour l'administration de thérapies à base d'arn

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired